Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHMG6X)

• Drug Name: SX-682 Drug Info
• Synonyms: 1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SX682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 1	[1]
Myelodysplastic syndrome	2A37	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 90467234
  CAS Number: CAS 1648843-04-2
  TTD Drug ID: DMHMG6X

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 1 (CXCR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[4]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[4]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[5]
INDOPROFEN	DM5QSKN	Gout	FA25	Withdrawn from market	[4]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[4]
2-(3-Isopropyl-phenyl)-propionic acid	DMUOWNE	Discovery agent	N.A.	Investigative	[4]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	DMWIUR0	Discovery agent	N.A.	Investigative	[4]
(R)-2-(4-Isobutyl-phenyl)-propionamide	DMBQ0PR	Discovery agent	N.A.	Investigative	[4]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	DMWRIQG	Discovery agent	N.A.	Investigative	[4]
2-[3-(2-Methyl-butyl)-phenyl]-propionic acid	DMKSDT4	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[4]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[6]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[4]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[7]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[8]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[9]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[3]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT03161431) SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04245397) SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy. U.S. National Institutes of Health.
• [3] Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
• [4] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
• [7] CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
• [8] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [9] Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
• [10] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [11] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [12] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [13] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.